ClinicalTrials.gg
RecruitingNCT06087536Updated Sep 28, 2026

A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

A Phase 2 interventional study of OMN6 and Placebo in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia, sponsored by Omnix Medical Ltd. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Omnix Medical Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Sep 28, 2026First site in Greece9 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.

02

Conditions studied

  • Hospital-acquired Bacterial Pneumonia
  • Ventilator-associated Bacterial Pneumonia

Browse trials for

Keywords

  • HABP VABP ABC Acinetobacter baumannii pneumonia
03

In context

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

This study's planned enrollment of 54 is below the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.

Browse Pneumonia, Bacterial studies →

Lead sponsor

This is the only study on the registry with Omnix Medical Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A signed form.
  2. Male or female patients 18 years or older
  3. A diagnosis of either a HABP or a VABP
  4. ABC infection of the lower respiratory tract suspected based on a positive rapid testing of respiratory specimens
  5. Women of (WOCBP) (i.e., not or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization.
  6. Acute Physiology and Chronic Health Evaluation II (APACHE II) score between 10 and 24

Exclusion criteria

Exclusion Criteria:

  1. Moderate to severe reduction of renal function
  2. Liver dysfunction
  3. Evidence of septic shock
  4. Acute respiratory distress syndrome.
  5. patients (due to either immunosuppressant drugs or to any medical condition).
  6. History of any known to colistin or to carbapenems
  7. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    OMN6 treatment

    OMN6 on top of Meropenem and Colistin

    Drug: OMN6

  • Placebo comparator
    Placebo

    Placebo on top of Meropenem and Colistin

    Drug: Placebo

Interventions

  • DrugOMN6

    Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day 3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days

  • DrugPlacebo

    3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days

06

What researchers measure

Primary outcomes

  1. To assess the safety of a single-day treatment with OMN6 vs. matching placebo when coadministered with a background therapy of meropenem and colistin

    Incidence of TEAE and SAEs by frequency, severity, relatedness, and outcome, clinical laboratory findings change from baseline, vital signs and ECGs change from baseline.

    Time frame: 28 day

  2. To asses the Cmax of OMN6 in patient population

    Maximum Observed Plasma Concentration

    Time frame: 1 day

  3. To assess the Tmax of OMN6 in patient population

    Time to Cmax

    Time frame: 1 day

  4. To assess the AUC of OMN6 in patient population

    Area Under the Plasma Concentration-Time Curve

    Time frame: 1 day

  5. To assess the t1/2 of OMN6 in patient population

    Time to Half-life

    Time frame: 1 day

07

Study locations

15 of 15 sites recruiting
  • Omnix Medical Research Site 1
    Athens, Greece
    Recruiting
  • Omnix Medical Research Site 2
    Athens, Greece
    Recruiting
  • Omnix Medical Research Site 3
    Athens, Greece
    Recruiting
  • Omnix Medical Research Site 4
    Athens, Greece
    Recruiting
  • Omnix Medical Research Site
    Ioannina, Greece
    Recruiting
  • Omnix Medical Research Site 1
    Thessaloniki, Greece
    Recruiting
  • Omnix Medical Research Site 2
    Thessaloniki, Greece
    Recruiting
  • Omnix Medical Research Site 3
    Thessaloniki, Greece
    Recruiting
  • Omnix Medical Research Site 4
    Thessaloniki, Greece
    Recruiting
  • Omnix Medical Research Site
    Ashdod, Israel
    Recruiting
  • Omnix Medical Research Site
    Be’er Ya‘aqov, Israel
    Recruiting
  • Omnix Medical Research Site
    Holon, Israel
    Recruiting
  • Omnix Medical Research Site
    Petah Tikva, Israel
    Recruiting
  • Omnix Medical Research Site
    Ramat Gan, Israel
    Recruiting
  • Omnix Medical Research Site
    Rishon LeZiyyon, Israel
    Recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Oct 17, 2023
StartActual
May 14, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in Greece
Show 9 added (9 Greece)
  • Omnix Medical Research Site 1 · Athens, Greece
  • Omnix Medical Research Site 2 · Athens, Greece
  • Omnix Medical Research Site 3 · Athens, Greece
  • Omnix Medical Research Site 4 · Athens, Greece
  • Omnix Medical Research Site · Ioannina, Greece
  • Omnix Medical Research Site 1 · Thessaloniki, Greece
  • Omnix Medical Research Site 2 · Thessaloniki, Greece
  • Omnix Medical Research Site 3 · Thessaloniki, Greece
  • Omnix Medical Research Site 4 · Thessaloniki, Greece
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    9 sites added — first site in Greece
    Show 9 added (9 Greece)
    • Omnix Medical Research Site 1 · Athens, Greece
    • Omnix Medical Research Site 2 · Athens, Greece
    • Omnix Medical Research Site 3 · Athens, Greece
    • Omnix Medical Research Site 4 · Athens, Greece
    • Omnix Medical Research Site · Ioannina, Greece
    • Omnix Medical Research Site 1 · Thessaloniki, Greece
    • Omnix Medical Research Site 2 · Thessaloniki, Greece
    • Omnix Medical Research Site 3 · Thessaloniki, Greece
    • Omnix Medical Research Site 4 · Thessaloniki, Greece

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06087536
Lead sponsor
Omnix Medical Ltd
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
May 14, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Bella Shusterman
Contact
bella@omnixmedical.com
+972 2 5320871

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion